» Articles » PMID: 22987690

Comparison of Analysis Approaches for Phase III Clinical Trials in Amyotrophic Lateral Sclerosis

Overview
Journal Muscle Nerve
Date 2012 Sep 19
PMID 22987690
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In this study we explore several methods for incorporating survival information in the analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) scores.

Methods: ALSFRS scores and patient survival times were simulated based on estimates from a recent clinical trial. Six analysis approaches were applied to the data. Each approach was based on ALSFRS scores, the survival time, or a combination of the 2. The power of each approach to detect potential treatment effects was estimated.

Results: When the treatment acted solely on the change in ALSFRS, the shared parameter model provided the most power, although all of the models based on random effects were similar. As the effect on survival increased, rank-based analysis showed potential gains in power. Survival analysis was superior under a small effect on ALSFRS and a larger effect on mortality.

Conclusions: The shared parameter model and rank-based approach can offer improvements in power over traditional approaches.

Citing Articles

Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.

de Jongh A, van Eijk R, Bakker L, Bunte T, Beelen A, van der Meijden C Neurology. 2023; 101(6):e602-e612.

PMID: 37311649 PMC: 10424842. DOI: 10.1212/WNL.0000000000207483.


A machine-learning based objective measure for ALS disease severity.

Vieira F, Venugopalan S, Premasiri A, McNally M, Jansen A, McCloskey K NPJ Digit Med. 2022; 5(1):45.

PMID: 35396385 PMC: 8993812. DOI: 10.1038/s41746-022-00588-8.


Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand.

van Eijk R, Roes K, de Greef-van der Sandt I, van den Berg L, Lu Y Clin Pharmacol Ther. 2022; 111(4):817-825.

PMID: 35076930 PMC: 8940672. DOI: 10.1002/cpt.2533.


Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.

van Eijk R, Eijkemans M, Rizopoulos D, van den Berg L, Nikolakopoulos S Clin Epidemiol. 2018; 10:333-341.

PMID: 29593436 PMC: 5865572. DOI: 10.2147/CLEP.S153196.


A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck E, Beal F, Marder K Neurology. 2016; 88(2):152-159.

PMID: 27913695 PMC: 5224719. DOI: 10.1212/WNL.0000000000003478.